Perspective Therapeutics, Inc. SEC filings CATX
Perspective Therapeutics, Inc. has 1,002 filings in SEC EDGAR's recent list, going back to Aug 16, 2006. Its latest annual report, Form 10-K, was filed on Mar 16, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 10, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 23, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| SD | Specialized disclosure (conflict minerals) | May 19, 2025 | — |
| EFFECT | Filing | Apr 8, 2025 | — |
| POSASR | Filing | Mar 26, 2025 | — |
| SD | Specialized disclosure (conflict minerals) | May 16, 2024 | — |
| EFFECT | Filing | Apr 9, 2024 | — |
| CORRESP | Letter to the SEC | Apr 8, 2024 | — |
| UPLOAD | Letter from the SEC | Apr 8, 2024 | — |
| D | Filing | Mar 18, 2024 | — |
| D | Filing | Jan 22, 2024 | — |
| EFFECT | Filing | Dec 14, 2023 | — |
| CORRESP | Letter to the SEC | Dec 13, 2023 | — |
| CORRESP | Letter to the SEC | Dec 6, 2023 | — |
| UPLOAD | Letter from the SEC | Nov 30, 2023 | — |
| SD | Specialized disclosure (conflict minerals) | Jun 14, 2023 | — |
| D | Filing | Feb 21, 2023 | — |
| SD | Specialized disclosure (conflict minerals) | May 26, 2022 | — |
| POS EX | Form pos ex | Jan 28, 2022 | — |
| SD | Specialized disclosure (conflict minerals) | May 27, 2021 | — |
| SD | Specialized disclosure (conflict minerals) | May 26, 2020 | — |
| EFFECT | Filing | Feb 4, 2020 | — |
| CORRESP | Letter to the SEC | Jan 31, 2020 | — |
| UPLOAD | Letter from the SEC | Jan 30, 2020 | — |
| SD | Specialized disclosure (conflict minerals) | May 10, 2019 | — |
| CT ORDER | Filing | Feb 26, 2019 | — |
| EFFECT | Filing | Dec 14, 2018 | — |
| CORRESP | Letter to the SEC | Dec 10, 2018 | — |
| UPLOAD | Letter from the SEC | Oct 31, 2018 | — |
| D | Filing | Jul 25, 2018 | — |
| SD | Specialized disclosure (conflict minerals) | May 25, 2018 | — |
| CT ORDER | Filing | Mar 9, 2018 | — |
| CT ORDER | Filing | Jan 22, 2018 | — |
| CT ORDER | Filing | Nov 27, 2017 | — |
| SD | Specialized disclosure (conflict minerals) | May 31, 2017 | — |
| CT ORDER | Filing | Feb 22, 2017 | — |
| CT ORDER | Filing | Feb 21, 2017 | — |
| CT ORDER | Filing | Feb 8, 2017 | — |
| SD | Specialized disclosure (conflict minerals) | May 31, 2016 | — |
| CT ORDER | Filing | Apr 20, 2016 | — |
| CT ORDER | Filing | Feb 11, 2016 | — |
| EFFECT | Filing | Dec 2, 2015 | — |
| CORRESP | Letter to the SEC | Nov 30, 2015 | — |
| UPLOAD | Letter from the SEC | Nov 30, 2015 | — |
| EFFECT | Filing | Nov 23, 2015 | — |
| CORRESP | Letter to the SEC | Nov 19, 2015 | — |
| CT ORDER | Filing | Nov 17, 2015 | — |
| UPLOAD | Letter from the SEC | Sep 21, 2015 | — |
| CT ORDER | Filing | Jun 23, 2015 | — |
| SD | Specialized disclosure (conflict minerals) | Jun 1, 2015 | — |
| CT ORDER | Filing | Nov 10, 2014 | — |
| CT ORDER | Filing | Oct 15, 2014 | — |
| CT ORDER | Filing | Jul 29, 2014 | — |
| CT ORDER | Filing | Jul 29, 2014 | — |
| SD | Specialized disclosure (conflict minerals) | Jun 2, 2014 | — |
| CT ORDER | Filing | Feb 18, 2014 | — |
| CT ORDER | Filing | Oct 24, 2013 | — |
| EFFECT | Filing | Jun 14, 2013 | — |
| CT ORDER | Filing | Jun 7, 2013 | — |
| EFFECT | Filing | Nov 23, 2012 | — |
| CT ORDER | Filing | Mar 2, 2012 | — |
| CT ORDER | Filing | Nov 23, 2011 | — |
| CT ORDER | Filing | Sep 12, 2011 | — |
| EFFECT | Filing | Jan 3, 2011 | — |
| CT ORDER | Filing | Aug 3, 2010 | — |
| UPLOAD | Letter from the SEC | Apr 8, 2010 | — |
| UPLOAD | Letter from the SEC | Jan 26, 2010 | — |
| CT ORDER | Filing | Jan 15, 2010 | — |
| CT ORDER | Filing | Jan 15, 2010 | — |
| CT ORDER | Filing | Jan 15, 2010 | — |
| EFFECT | Filing | Nov 13, 2009 | — |
| CT ORDER | Filing | May 21, 2009 | — |
| CT ORDER | Filing | Feb 5, 2009 | — |
| EFFECT | Filing | Oct 14, 2008 | — |
| EFFECT | Filing | Oct 14, 2008 | — |
| AW | Filing | Nov 21, 2007 | — |
| AW | Filing | Nov 21, 2007 | — |
| EFFECT | Filing | Nov 20, 2007 | — |
| EFFECT | Filing | Nov 20, 2007 | — |
| 10KSB | Filing | Sep 28, 2007 | Jun 30, 2007 |
| 10QSB | Filing | May 15, 2007 | Mar 31, 2007 |
| CERTAMX | Auto-generated paper document | Apr 19, 2007 | — |
| UPLOAD | Letter from the SEC | Apr 13, 2007 | — |
| 8-A12B | Filing | Apr 12, 2007 | — |
| UPLOAD | Letter from the SEC | Apr 4, 2007 | — |
| CORRESP | Letter to the SEC | Mar 30, 2007 | — |
| CORRESP | Letter to the SEC | Feb 26, 2007 | — |
| EFFECT | Filing | Feb 15, 2007 | — |
| 10QSB | Filing | Feb 14, 2007 | Dec 31, 2006 |
| UPLOAD | Letter from the SEC | Feb 12, 2007 | — |
| 8-A12G | Filing | Feb 7, 2007 | — |
| EFFECT | Filing | Dec 5, 2006 | — |
| EFFECT | Filing | Dec 5, 2006 | — |
| AW | Filing | Nov 30, 2006 | — |
| SB-2/A | Filing | Nov 17, 2006 | — |
| SB-2/A | Filing | Nov 17, 2006 | — |
| 10QSB | Filing | Nov 14, 2006 | Sep 30, 2006 |
| UPLOAD | Letter from the SEC | Nov 14, 2006 | — |
| UPLOAD | Letter from the SEC | Nov 8, 2006 | — |
| UPLOAD | Letter from the SEC | Nov 8, 2006 | — |
| EFFECT | Filing | Oct 27, 2006 | — |
| SB-2/A | Filing | Oct 19, 2006 | — |
| EFFECT | Filing | Oct 17, 2006 | — |
| SB-2 | Filing | Oct 16, 2006 | — |
| 10KSB | Filing | Sep 28, 2006 | Jun 30, 2006 |
| REGDEX | Auto-generated paper document | Aug 25, 2006 | — |
Showing 104 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CATX (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Seattle, WA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 728387
- Former names
- IsoRay, Inc. (until Feb 16, 2023); Isoray, Inc. (until Feb 16, 2023); CENTURY PARK PICTURES CORP (until Aug 3, 2005)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.